HLS Therapeutics's dividends per share for the
three
months ended in Mar. 2026 was C$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was C$0.00. Its Dividend Payout Ratio for the
three
months ended in Mar. 2026 was 0.00. As of today, HLS Therapeutics's Dividend Yield % is 0.00%.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of HLS Therapeutics was 59.00% per year. The lowest was -19.50% per year. And the median was 22.80% per year.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
HLS Therapeutics (TSX:HLS) Dividends per Share Explanation
1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.
HLS Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
During the past 13 years, the highest Dividend Yield of HLS Therapeutics was 4.84%. The lowest was 0.32%. And the median was 1.27%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLS Therapeutics Dividends per Share Related Terms
HLS Therapeutics Dividends per Share Historical Data
* Premium members only.
The historical data trend for HLS Therapeutics's Dividends per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSX:HLS vs ZTS, UTHR: Dividends per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's Dividend Yield % falls into.
HLS Therapeutics (TSX:HLS) has a Dividends per Share of C$0.00 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on HLS Therapeutics and its competitors.
Is HLS Therapeutics' Dividends per Share too high?
HLS Therapeutics' current Dividends per Share is C$0.00. Overall, HLS Therapeutics has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Dividends per Share compare to ZTS and UTHR?
HLS Therapeutics' Dividends per Share of C$0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Drug Manufacturers company?
A good Dividends per Share depends on the Drug Manufacturers industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on HLS Therapeutics and its competitors. HLS Therapeutics's current Dividends per Share is C$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.50, compared to a current price of C$4.20 — trading 6.7% below its estimated fair value. The current Dividends per Share is C$0.00. HLS Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Dividends per Share is C$0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$4.20 is trading 6.7% below its estimated GF Value™ of C$4.50.
GuruFocus considers HLS Therapeutics to be Fairly Valued.
Key valuation signals for TSX:HLS:
Dividends per Share: C$0.00
GF Value™: C$4.50 vs. price of C$4.20 (6.7% below fair value)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
66GF Score
Get the complete analysis for TSX:HLS
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 
